589 related articles for article (PubMed ID: 24618042)
21. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
22. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.
Ochoa MC; Minute L; Rodriguez I; Garasa S; Perez-Ruiz E; Inogés S; Melero I; Berraondo P
Immunol Cell Biol; 2017 Apr; 95(4):347-355. PubMed ID: 28138156
[TBL] [Abstract][Full Text] [Related]
23. Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside.
Woan KV; Miller JS
Cancer Immunol Res; 2019 Nov; 7(11):1742-1747. PubMed ID: 31676567
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cell adoptive immunotherapy: Coming of age.
Baggio L; Laureano ÁM; Silla LMDR; Lee DA
Clin Immunol; 2017 Apr; 177():3-11. PubMed ID: 26883680
[TBL] [Abstract][Full Text] [Related]
25. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
Tay SS; Carol H; Biro M
Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
[TBL] [Abstract][Full Text] [Related]
26. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
[TBL] [Abstract][Full Text] [Related]
27. The biology of natural killer cells and implications for therapy of human disease.
Chiorean EG; Miller JS
J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
[TBL] [Abstract][Full Text] [Related]
28. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
29. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
30. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.
Brehm C; Huenecke S; Quaiser A; Esser R; Bremm M; Kloess S; Soerensen J; Kreyenberg H; Seidl C; Becker PS; Mühl H; Klingebiel T; Bader P; Passweg JR; Schwabe D; Koehl U
PLoS One; 2011; 6(11):e27351. PubMed ID: 22096557
[TBL] [Abstract][Full Text] [Related]
31. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
32. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
33. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
34. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
Felices M; Lenvik TR; Davis ZB; Miller JS; Vallera DA
Methods Mol Biol; 2016; 1441():333-46. PubMed ID: 27177679
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
37. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.
Xiong Y; Mouginot M; Reppel L; Qian C; Stoltz JF; Bensoussan D; Decot V
Immunol Res; 2017 Dec; 65(6):1130-1138. PubMed ID: 29019081
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human natural killer cells for therapeutic use.
Wagner AK; Alici E; Lowdell MW
Cytotherapy; 2019 Mar; 21(3):315-326. PubMed ID: 30910383
[TBL] [Abstract][Full Text] [Related]
39. Improving natural killer cell cancer immunotherapy.
Berrien-Elliott MM; Romee R; Fehniger TA
Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
[TBL] [Abstract][Full Text] [Related]
40. Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials.
Suen WC; Lee WY; Leung KT; Pan XH; Li G
Cancer Invest; 2018; 36(8):431-457. PubMed ID: 30325244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
